Counteracting drug-induced obesity using GLP-1 agonists

• US 8,410,047 B2
• Filed: 05/31/2005
• Issued: 04/02/2013
• Est. Priority Date: 06/11/2004
• Status: Active Grant

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Bock, Camilla, Knudsen, Sanne Mller, Rimvall, Karin
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US11/629,238
• Publication Number:
  US 20090054315A1
• Time in Patent Office: 2,863 Days
• Field of Search: None
• US Class Current: 514/4.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.

Claims

1. A method of treating antipsychotic drug-induced obesity in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a GLP-1 agonist for reducing body weight in said subject administered an atypical antipsychotic drug, wherein the GLP-1 agonist is Arg³⁴Lys²⁶(N^ε

-(γ

-Glu(N^ε

-hexadecanoyl)))-GLP-1 (7-37).

2. The method of claim 1, wherein the atypical antipsychotic is selected from amisulpride, sulpiride, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.

3. The method of claim 1, wherein the atypical antipsychotic is clozapine.

4. The method of claim 1, wherein the atypical antipsychotic is olanzapine.

5. The method of claim 1, wherein the subject has a body mass index (BMI) of at least 30.

6. The method of claim 1, wherein the subject has a BMI of at least 27.

7. The method of claim 1, wherein the subject has a BMI of at least 25.

8. The method of claim 1, wherein the subject'"'"'s weight is about 7% over ideal.

9. The method of claim 1, wherein the subject, within the past year of drug treatment, has gained about 1, 2, 3, 4, 5, 6, or 7% body weight.

10. The method of claim 1, wherein the subject, within the past year of drug treatment, has gained about 7% body weight.

11. The method of claim 1, wherein the subject, within the past six months of drug treatment, has gained about 7% body weight.

12. The method of claim 1, wherein the GLP-1 agonist is administered concurrently with the daily dosage of obesity-inducing drug.

13. The method of claim 1, wherein the GLP-1 agonist is administered prior to the daily dosage of obesity-inducing drug.

14. The method of claim 1, wherein the GLP-1 agonist is administered after the daily dosage of obesity-inducing drug.

15. The method of claim 1, wherein the GLP-1 agonist is administered to the subject prior to the onset of obesity.

16. The method of claim 1, wherein the GLP-1 agonist is administered at the start of the subject'"'"'s obesity-inducing drug therapy.

17. The method of claim 1, wherein the GLP-1 agonist is administered in connection with a meal.